Almirall takes option on Dermira's eczema drug lebrikizumab

Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron's recently approved Dupixent.

Sanofi/Regeneron asthma trial casts doubt on IL-33 class pro...

FDA approves Regeneron's Eylea for diabetic retinopathy

Regeneron’s Eylea injection has been approved in the US for diabetic retinopathy, to treat all stages of the disease and reduce the risk of blindness.

Sanofi claims EU okay for Dupixent in asthma

Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic.

Cholesterol drug from Sanofi/Regeneron gains US CV risk redu...

Sanofi and Regeneron’s Praluent cholesterol drug has been approved in the US to help prevent cardiovascular events, a new indication that will help it compete with Amgen’s rival from the sa

Sanofi/Regeneron skin cancer drug among flurry of decisions ...

A new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group of new drugs that look set for the European market following backing from regulators.